Case Studies – The Catapult Network

Browse Catapults

Case Studies from across the Catapults

Search

Themes (Reset)

Catapults (Reset)

Cross-Catapult (2),
Cell and Gene Therapy (15),
Compound Semiconductor Applications (13),
Connected Places (14),
Digital (15),
Energy Systems (14),
High Value Manufacturing (17),
Medicines Discovery (14),
Offshore Renewable Energy (15),
Satellite Applications (14),

Catapults

Medicines Discovery

alt=

How do we supercharge and sustain skills in UK Life Sciences?

Medicines Discovery Catapult is reshaping drug discovery for patient benefit by transforming great UK science into better treatments through partnership. The life sciences industry is critical to the UK’s health, wealth, and resilience. Attracting, recruiting, training, and retaining a skilled workforce is key to ongoing success in this critical sector.

Medicines Discovery

How do we supercharge and sustain skills in UK Life Sciences?

Medicines Discovery Catapult is reshaping drug discovery for patient benefit by transforming great UK science into better treatments through partnership. The life sciences industry is critical to the UK’s health, wealth, and resilience. Attracting, recruiting, training, and retaining a skilled workforce is key to ongoing success in this critical sector.

Medicines Discovery

Bolstering the North West’s position as a life science powerhouse

Medicines Discovery Catapult is driving regional growth in the North West of England, supporting the region’s fast-growing and increasingly significant life science industry.

Medicines Discovery

Launch of a drug discovery consortium to address the unmet therapeutic needs of people living with mental health conditions

The Psychiatry Consortium is a £4 million international collaboration between seven global pharmaceutical companies and two leading medical research charities, convened and managed by Medicines Discovery Catapult, to support high-value drug discovery projects that address the unmet therapeutic needs of people living with mental health conditions, including psychiatric symptoms associated with dementia.

Cell and Gene Therapy

alt=

Growing new capabilities with German company Rentschler Biopharma SE

Cell and Gene Therapy Catapult partnered with German based Rentschler Biopharma to enable the establishment of new ATMP development and manufacturing capabilities in the UK, to benefit the UK and international demand and further strengthen the UK ecosystem and international supply chain.

Medicines Discovery

alt=

Highlighting the role of women in science and innovation

By championing innovative life science technology and new approaches, Medicines Discovery Catapult is supporting UK innovators to succeed. Medicines Discovery Catapult recognises that diversity in the workforce underpins the creative and innovative thinking essential for success in this sector.

High Value Manufacturing

alt=

Northern Bio-Accelerator Partnership to create bioscience hub in the Tees Valley

Northern Bio-Accelerator Partnership to create bioscience hub in the Tees Valley

High Value Manufacturing

Northern Bio-Accelerator Partnership to create bioscience hub in the Tees Valley

Northern Bio-Accelerator Partnership to create bioscience hub in the Tees Valley

Cell and Gene Therapy

alt=

Advancing acute myeloid leukaemia cell therapy

A collaboration between the Cell and Gene Therapy Catapult, University College London and Imperial College London advances a novel cell therapy for the treatment of acute myeloid leukaemia.

Cell and Gene Therapy

Advancing acute myeloid leukaemia cell therapy

A collaboration between the Cell and Gene Therapy Catapult, University College London and Imperial College London advances a novel cell therapy for the treatment of acute myeloid leukaemia.

Cell and Gene Therapy

Developing treatments for chronic kidney disease

University spin-out Purespring Therapeutics sought expert input from the Cell and Gene Therapy Catapult to efficiently progress their pre-clinical development plans and secured one of the largest single investment to a UK biotech company from global healthcare giant Syncona.

Medicines Discovery

Innovative treatments for a longer healthy, independent life

Figures show that we are spending more of our lives in poor health. In response, a national network is bringing together scientific expertise from across the UK to shed new light on the ageing process and help us stay healthy for longer.

Medicines Discovery

alt=

International biobank provides database for cancer researchers worldwide

Medicines Discovery Catapult collaborated with Manchester University to create a sustainable model for a biorepository providing a critical data for researchers investigating patient side-effects from radiotherapy.

Satellite Applications

alt=

Connecting Emergency Responders

With support from the Satellite Applications Catapult, Excelerate Technology, pioneers of the provision of resilient, zero-gap connectivity in the Emergency Responder market, is leading work to design, develop and deliver major advancements in coastal connectivity.

Medicines Discovery

alt=

Mobilising national high scale COVID-19 testing

In March 2020, the UK government announced the launch of a national testing effort to support the UK’s fight against coronavirus via the establishment of a network of high-scale testing laboratories, known as “Lighthouse Labs”.

Medicines Discovery

Mobilising national high scale COVID-19 testing

In March 2020, the UK government announced the launch of a national testing effort to support the UK’s fight against coronavirus via the establishment of a network of high-scale testing laboratories, known as “Lighthouse Labs”.

Medicines Discovery

alt=

Developing new treatments to prevent thrombosis

LUNAC Therapeutics, a UK based drug discovery company, together with the Medicines Discovery Catapult and the University of Leeds, are working on the development of an innovative first-in-class anticoagulant treatment drug with minimal bleeding risk.

Medicines Discovery

Developing new treatments to prevent thrombosis

LUNAC Therapeutics, a UK based drug discovery company, together with the Medicines Discovery Catapult and the University of Leeds, are working on the development of an innovative first-in-class anticoagulant treatment drug with minimal bleeding risk.

High Value Manufacturing

Technician building a ventilator

Delivering vital medical equipment, saving lives

Following a call with the Prime Minister, Dick Elsy, CEO of the High Value Manufacturing Catapult convened an industrial consortium to support produce vital ventilator devices and support the NHS in its fight against Covid-19.

Cell and Gene Therapy

Pioneering technology to increase effectiveness of gene therapeutics

A collaboration between the Cell and Gene Therapy Catapult and Synpromics set out to develop novel scalable manufacturing processes and technologies to produce viral vectors at scale.

Cell and Gene Therapy

alt=

Enabling the development of potentially life-saving therapies

The emergence of cell therapies will potentially change the landscape of healthcare. The Cell and Gene Therapy Catapult, identified the need for a cell thawing system that would reduce barriers to the commercialisation.

Cell and Gene Therapy

alt=

Developing large scale manufacture and supply of cell and gene therapies

The Cell and Gene Therapy Catapult Manufacturing Centre facilitates collaborating companies to produce living medicines at scale, supporting clinical trials and commercial supply.

Medicines Discovery

alt=

Discovery Services platform boosts UK life sciences R&D and international competitiveness

The Medicines Discovery Catapult Virtual R&D Discovery Services platform helps match UK SMEs to access medicines and drug discovery services and state-of-the-art equipment, enabling deeper market penetration and access to a wider network of customers.

Medicines Discovery

Discovery Services platform boosts UK life sciences R&D and international competitiveness

The Medicines Discovery Catapult Virtual R&D Discovery Services platform helps match UK SMEs to access medicines and drug discovery services and state-of-the-art equipment, enabling deeper market penetration and access to a wider network of customers.

Page 1 of 1